Jefferies Group LLC Reiterates Buy Rating for Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
Karyopharm Therapeutics Inc. (NASDAQ:KPTI)‘s stock had its “buy” rating restated by equities research analysts at Jefferies Group LLC in a report issued on Friday. They currently have a $16.00 price objective on the stock. Jefferies Group LLC’s target price would suggest a potential upside of 69.49% from the company’s current price.
A number of other analysts have also issued reports on KPTI. HC Wainwright reissued a “buy” rating and issued a $14.00 target price on shares of Karyopharm Therapeutics in a research report on Friday, March 17th. Zacks Investment Research raised Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 21st. Wedbush reaffirmed an “outperform” rating and set a $14.00 price objective on shares of Karyopharm Therapeutics in a research report on Wednesday, April 5th. Robert W. Baird reaffirmed an “outperform” rating and set a $15.00 price objective on shares of Karyopharm Therapeutics in a research report on Thursday, April 6th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $18.00 price objective on shares of Karyopharm Therapeutics in a research report on Monday, May 15th. One equities research analyst has rated the stock with a sell rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $14.46.
Karyopharm Therapeutics (KPTI) traded down 1.56% on Friday, reaching $9.44. The company’s stock had a trading volume of 111,499 shares. The company has a 50 day moving average of $9.29 and a 200 day moving average of $10.20. Karyopharm Therapeutics has a 52 week low of $6.27 and a 52 week high of $14.63. The firm’s market capitalization is $444.79 million.
Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Thursday, May 4th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by $0.04. The firm had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.02 million. Karyopharm Therapeutics had a negative net margin of 50,646.40% and a negative return on equity of 72.41%. During the same period in the previous year, the firm earned ($0.75) EPS. On average, analysts forecast that Karyopharm Therapeutics will post ($2.68) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This story was first reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2017/07/15/jefferies-group-llc-reiterates-buy-rating-for-karyopharm-therapeutics-inc-nasdaqkpti.html.
A number of institutional investors have recently bought and sold shares of KPTI. Teza Capital Management LLC acquired a new position in Karyopharm Therapeutics during the first quarter valued at approximately $169,000. Swiss National Bank raised its position in Karyopharm Therapeutics by 10.9% in the first quarter. Swiss National Bank now owns 40,850 shares of the company’s stock valued at $525,000 after buying an additional 4,000 shares during the period. Bank of New York Mellon Corp raised its position in Karyopharm Therapeutics by 61.7% in the first quarter. Bank of New York Mellon Corp now owns 181,602 shares of the company’s stock valued at $2,332,000 after buying an additional 69,315 shares during the period. C WorldWide Group Holding A S raised its position in Karyopharm Therapeutics by 30.2% in the first quarter. C WorldWide Group Holding A S now owns 16,928 shares of the company’s stock valued at $217,000 after buying an additional 3,928 shares during the period. Finally, Wells Fargo & Company MN raised its position in Karyopharm Therapeutics by 114.6% in the first quarter. Wells Fargo & Company MN now owns 43,606 shares of the company’s stock valued at $560,000 after buying an additional 23,284 shares during the period. 57.11% of the stock is currently owned by hedge funds and other institutional investors.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.